Sysmex (6869.T) Akcie Kurz
Sysmex Kurz
Tržby rostly o 8,8 % ročně za posledních 19 let na 500,01 Mld. JPY. Zisk na akcii rostl o 7,5 % ročně za posledních 19 let. čistá marže společnosti Sysmex je nyní 7,1 %, dolů z 12,1 % před několika lety. Sysmex aktuálně nabízí dividendový výnos kolem 2,93 %. Výplatní poměr je kolem 39 % zisku. Dividenda rostla o 15,9 % ročně za posledních 19 let. Medián cílové ceny analytiků je 2 320,50 JPY, tedy nad aktuální cenu o 23,8 %. Z 21 analytiků jich 16 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Sysmex
Obchodní model Sysmex a analýza akcií
Nejčastější otázky týkající se akcie Sysmex
Sysmex Corp is a leading healthcare company specializing in diagnostic testing equipment and technologies. The business model of Sysmex Corp revolves around the design, development, and manufacture of innovative testing systems for clinical laboratories and healthcare institutions. With a strong focus on hematological analysis and hemostasis, Sysmex Corp provides highly accurate and reliable diagnostic solutions to support disease detection, monitoring, and treatment. By leveraging advanced technologies and automation, the company enables efficient and precise diagnostic processes, ultimately contributing to better patient outcomes. Sysmex Corp's business model centers on delivering cutting-edge diagnostic solutions that empower healthcare professionals with the tools they need for accurate and timely diagnoses.
Sysmex Corp is primarily active in the healthcare and medical technology industries.
The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).
Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.
Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.
Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.
Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.
Analytici aktuálně stanovují průměrnou cílovou cenu 2 391,26 JPY pro akcii Sysmex (medián: 2 320,50 JPY), tedy +27,6 % vůči poslední ceně. Konsensus vychází z 21 hodnocení analytiků.
21 analytiků aktuálně hodnotí akcii Sysmex: 16 doporučuje koupit, 5 držet a 0 prodat.
Při aktuálním kurzu se akcie Sysmex obchoduje za 10,58 EUR (1 874,50 JPY).
Akcie Sysmex (6869.T) je kótována na 4 burzách, mimo jiné: Tokio (JPX) (6869.T), Frankfurt (0YX.F), München (0YX.MU).
Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.
Tržby za Sysmex činí 500,01 Mld. JPY. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk za Sysmex činí 35,46 Mld. JPY. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Sysmex je aktuálně 32,42. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Sysmex.
Poměr ceny k tržbám (P/S) Sysmex je aktuálně 2,30. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Sysmex.
Score kvality pro Sysmex je 6/10.
ISIN Sysmex je JP3351100007. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Sysmex je 897966. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Sysmex je 6869.T. Symbol tickeru se používá k obchodování akcií Sysmex na burze.
Sysmex akcie
Sysmex Ticker
Sysmex FIGI
Všechny fundamentální údaje o Sysmex v podrobné analýze
Naše analýzy akcií společnosti Sysmex zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Sysmex. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: